Osteoporosis Drugs Market 2019 Global Market Size and Share, Trends, Top Key Players, Industry 2023

Global osteoporosis drugs market size will grow by USD 1.85 billion during 2019-2023, at a CAGR of almost 5%. The demand for transdermal delivery system is increasing as it shows prolonged action by enhancing the bioavailability of drugs to the targeted site. It not only reduces the adverse effects of drugs but also effectively treats osteoporosis. The adoption of transdermal delivery system as a new route of administration has improved drug compliance. Novel teriparatide transdermal microneedle delivery system is one such transdermal delivery system and administered as a daily subcutaneous injection.

New drug approvals and favorable pipeline

Osteoporosis increases the risk of fracture particularly in spines and wrists due to low bone mass and tissue loss. The growing prevalence of osteoporosis is resulting in an increased demand for anabolic agents that can increase bone mass and improve its quality by promoting new bone formation. Antiresorptive and anabolic medications are considered as more effective and targeted approaches in osteoporosis treatment. The development and testing of such drugs will lead to favorable drug pipeline for osteoporosis.

Request for a FREE sample and get selected illustrations, table of contents, list of exhibits, and example pages from this report.

"The high prevalence of osteoporosis resulting from alcohol consumption, rheumatoid arthritis, and cigarette smoking will drive the osteoporosis drugs market growth in North America. Additionally, the high incidence of osteoporosis in older women and high sales of drugs in the US will also drive the growth of the market in North America," says an analyst at Technavio.

The concentration of vendors that develop osteoporosis drugs is high in the US. They are forming strategic alliances to develop better drugs for the treatment of osteoporosis. They are collaborating with institutes under a license agreement to research and market antibody products that target the protein sclerostin. Major markets including France, Canada, Germany, Japan, the UK, and the US are providing reimbursement schemes, which will boost the demand and adoption of osteoporosis therapeutics.

View snapshot of the report for a more detailed overview of the market and the segmentation covered in this report

This osteoporosis drugs industry research report provides an in-depth analysis of the major drivers, upcoming trends, and challenges that will impact market growth over the forecast period. The report analyzes the competitive landscape and offers details on several osteoporosis drugs manufacturers including -

• Amgen Inc.
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc.
• Radius Health Inc.

Some of the key topics covered in the report include:

Market Landscape

• Market ecosystem
• Market characteristics
• Market segmentation analysis

Market Sizing

• Market definition
• Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

• Regional comparison
• Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. Technavio’s report library consists of more than 10,000 reports covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies.

Please contact our media team at media@technavio.com for more information

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com